Description
Sermorelin is a synthetic analogue of growth hormone-releasing hormone, consisting of the first 29 amino acids of endogenous GHRH with a C-terminal amide — the shortest fragment retaining full activity of the parent hormone.
What you are buying
A single 5 mg vial of lyophilised sermorelin from batch VL-2705-C, with identity confirmed by LC-MS against the expected mass of 3357.88 g/mol. The certificate of analysis is published in full.
The one compound here with an approval history
Sermorelin held FDA approval and was marketed as Geref. It was discontinued from the United States market in 2008, and that discontinuation is documented as a commercial decision rather than a safety withdrawal. It is the only compound in this catalogue to have been through a full regulatory evidence review.
Because it went through pharmaceutical development, the literature includes controlled human pharmacokinetic and pharmacodynamic work rather than being purely preclinical. The research overview covers that history, and the class comparison explains why we stock this GHRH analogue and not others in the wider secretagogue category.
Handling
At 29 residues this is the largest peptide in our catalogue, with correspondingly more sites vulnerable to hydrolysis, oxidation and aggregation. Handle gently — no vortexing — and inspect reconstituted stock for clarity before use. See the reconstitution guide.
